EGRX
Eagle Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.25
+0.00 (+0.00%)
Current Price
| Previous Close | $0.25 |
| Open | $1.50 |
| Day High | $1.50 |
| Day Low | $1.50 |
| Volume | 100 |
Stock Information
| Shares Outstanding | 13.16M |
| Total Debt | $72.45M |
| Cash Equivalents | $15.35M |
| Revenue | $257.55M |
| Net Income | $11.95M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $3.29M |
| P/E Ratio | 1.56 |
| EPS (TTM) | $0.16 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $65.09M |
| Sales | $257.55M |
| Income | $11.95M |
| Book/sh | $19.25 |
| Cash/sh | $1.17 |
| Employees | 134 |
Financial Ratios
| Quick Ratio | 1.51 |
| Current Ratio | 2.16 |
| Debt/Eq | 28.75 |
Returns & Margins
| ROA | 6.63% |
| ROE | 4.88% |
| Gross Margin | 69.84% |
| Operating Margin | 15.94% |
| Profit Margin | 4.64% |
Ownership
| Institutional Ownership | 55.20% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 0.07 |
| P/S | 0.01 |
| P/B | 0.01 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.59 |
| SMA50 | $0.46 |
| SMA200 | $0.86 |
| RSI | 54.88 |
| ATR | 0.2516 |
| Shares Float | 5.91M |
| Short Float | 4.19% |
| Short Ratio | 3.91 |
| Volatility | 0.66 |
Performance History
| Week | +0.82% |
| Month | +68.49% |
| Quarter | +623.53% |
| 6 Months | +515.00% |
| YTD | +80.88% |
| Year | -73.83% |
| 3 Years | -96.71% |
| 5 Years | -98.49% |
| 10 Years | -98.49% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.62 | 0 |
| 2026-06-17 | $0.62 | 0 |
| 2026-06-16 | $0.62 | 0 |
| 2026-06-15 | $0.62 | 400 |
| 2026-06-12 | $0.60 | 9,400 |
| 2026-06-11 | $0.61 | 0 |
| 2026-06-10 | $0.61 | 1,000 |
| 2026-06-09 | $0.60 | 0 |
| 2026-06-08 | $0.60 | 0 |
| 2026-06-05 | $0.60 | 300 |
| 2026-06-04 | $0.52 | 3,300 |
| 2026-06-03 | $0.65 | 400 |
| 2026-06-02 | $0.70 | 0 |
| 2026-06-01 | $0.70 | 14,100 |
| 2026-05-29 | $0.57 | 0 |
| 2026-05-28 | $0.57 | 0 |
| 2026-05-27 | $0.57 | 0 |
| 2026-05-26 | $0.57 | 4,200 |
| 2026-05-22 | $0.38 | 5,500 |
| 2026-05-21 | $0.37 | 300 |
| 2026-05-20 | $0.37 | 0 |
| 2026-05-19 | $0.37 | 1,500 |
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
đ° Latest News
No news articles available at the moment. Check back later for updates on EGRX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Revenue | ||
| Reconciled Cost Of Revenue | $94,936,000 | $42,180,000 |
| Cost Of Revenue | $94,936,000 | $42,180,000 |
| Total Revenue | $316,610,000 | $171,546,000 |
| Operating Revenue | $316,610,000 | $171,546,000 |
| Expenses | ||
| Interest Expense | $4,045,000 | $1,635,000 |
| Total Expenses | $235,650,000 | $168,777,000 |
| Other Income Expense | $-15,753,000 | $-6,242,000 |
| Other Non Operating Income Expenses | $-15,753,000 | $-6,242,000 |
| Net Non Operating Interest Income Expense | $-3,774,000 | $-1,075,000 |
| Interest Expense Non Operating | $4,045,000 | $1,635,000 |
| Operating Expense | $140,714,000 | $126,597,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $35,642,000 | $-8,627,000 |
| Net Interest Income | $-3,774,000 | $-1,075,000 |
| Interest Income | $271,000 | $560,000 |
| Normalized Income | $35,642,000 | $-8,627,000 |
| Net Income From Continuing And Discontinued Operation | $35,642,000 | $-8,627,000 |
| Total Operating Income As Reported | $80,960,000 | $2,769,000 |
| Net Income Common Stockholders | $35,642,000 | $-8,627,000 |
| Net Income | $35,642,000 | $-8,627,000 |
| Net Income Including Noncontrolling Interests | $35,642,000 | $-8,627,000 |
| Net Income Continuous Operations | $35,642,000 | $-8,627,000 |
| Pretax Income | $61,433,000 | $-4,548,000 |
| Interest Income Non Operating | $271,000 | $560,000 |
| Operating Income | $80,960,000 | $2,769,000 |
| Gross Profit | $221,674,000 | $129,366,000 |
| Per Share | ||
| Diluted EPS | $2.73 | $-0.66 |
| Basic EPS | $2.76 | $-0.66 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $77,502,000 | $847,000 |
| Reconciled Depreciation | $12,024,000 | $3,760,000 |
| EBITDA (Bullshit earnings) | $77,502,000 | $847,000 |
| EBIT | $65,478,000 | $-2,913,000 |
| Diluted Average Shares | $13,065,494 | $13,051,095 |
| Basic Average Shares | $12,933,896 | $13,051,095 |
| Diluted NI Availto Com Stockholders | $35,642,000 | $-8,627,000 |
| Tax Provision | $25,791,000 | $4,079,000 |
| Research And Development | $34,088,000 | $51,275,000 |
| Selling General And Administration | $106,626,000 | $75,322,000 |
Fetched: 2026-02-06
Balance Sheet (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $70,200,000 | $126,039,000 |
| Total Assets | $406,160,000 | $253,732,000 |
| Total Non Current Assets | $217,406,000 | $81,126,000 |
| Other Non Current Assets | $25,732,000 | $10,278,000 |
| Non Current Deferred Assets | $27,146,000 | $18,798,000 |
| Non Current Deferred Taxes Assets | $27,146,000 | $18,798,000 |
| Goodwill And Other Intangible Assets | $163,360,000 | $50,414,000 |
| Other Intangible Assets | $118,327,000 | $10,671,000 |
| Current Assets | $188,754,000 | $172,606,000 |
| Other Current Assets | $3,259,000 | $1,400,000 |
| Prepaid Assets | $8,940,000 | $4,831,000 |
| Inventory | $47,794,000 | $21,908,000 |
| Receivables | $73,440,000 | $46,808,000 |
| Other Receivables | $1,001,000 | $347,000 |
| Notes Receivable | $0 | $5,312,000 |
| Accounts Receivable | $72,439,000 | $41,149,000 |
| Cash Cash Equivalents And Short Term Investments | $55,321,000 | $97,659,000 |
| Cash And Cash Equivalents | $55,321,000 | $97,659,000 |
| Debt | ||
| Net Debt | $7,145,000 | - |
| Total Debt | $64,000,000 | $26,916,000 |
| Long Term Debt And Capital Lease Obligation | $56,216,000 | $2,904,000 |
| Long Term Debt | $56,216,000 | - |
| Current Debt And Capital Lease Obligation | $7,784,000 | $26,916,000 |
| Current Debt | $6,250,000 | $25,607,000 |
| Other Current Borrowings | $6,250,000 | $25,607,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $172,600,000 | $77,279,000 |
| Total Non Current Liabilities Net Minority Interest | $61,513,000 | $2,903,000 |
| Other Non Current Liabilities | $5,297,000 | $2,903,000 |
| Current Liabilities | $111,087,000 | $74,376,000 |
| Other Current Liabilities | $10,842,000 | $6,177,000 |
| Payables And Accrued Expenses | $92,461,000 | $41,283,000 |
| Payables | $46,380,000 | $21,516,000 |
| Other Payable | $22,205,000 | $5,085,000 |
| Total Tax Payable | $5,182,000 | $0 |
| Income Tax Payable | $5,182,000 | $0 |
| Accounts Payable | $18,993,000 | $16,431,000 |
| Equity | ||
| Common Stock Equity | $233,560,000 | $176,453,000 |
| Total Equity Gross Minority Interest | $233,560,000 | $176,453,000 |
| Stockholders Equity | $233,560,000 | $176,453,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,112,000 | $-94,000 |
| Other Equity Adjustments | $-1,112,000 | $-94,000 |
| Retained Earnings | $111,504,000 | $75,862,000 |
| Other | ||
| Treasury Shares Number | $4,552,730 | $4,111,622 |
| Ordinary Shares Number | $13,016,645 | $12,791,412 |
| Share Issued | $17,569,375 | $16,903,034 |
| Tangible Book Value | $70,200,000 | $126,039,000 |
| Invested Capital | $296,026,000 | $202,060,000 |
| Working Capital | $77,667,000 | $98,230,000 |
| Capital Lease Obligations | $1,534,000 | $1,309,000 |
| Total Capitalization | $289,776,000 | $176,453,000 |
| Treasury Stock | $243,115,000 | $225,111,000 |
| Additional Paid In Capital | $366,265,000 | $325,779,000 |
| Capital Stock | $18,000 | $17,000 |
| Common Stock | $18,000 | $17,000 |
| Preferred Stock | $0 | $0 |
| Long Term Capital Lease Obligation | $3,789,000 | $2,904,000 |
| Current Capital Lease Obligation | $1,534,000 | $1,309,000 |
| Current Accrued Expenses | $46,081,000 | $19,767,000 |
| Goodwill | $45,033,000 | $39,743,000 |
| Net PPE | $1,168,000 | $1,636,000 |
| Accumulated Depreciation | $-6,601,000 | $-5,955,000 |
| Gross PPE | $7,769,000 | $7,591,000 |
| Leases | $1,155,000 | $1,155,000 |
| Other Properties | $4,012,000 | $3,834,000 |
| Machinery Furniture Equipment | $2,602,000 | $2,602,000 |
| Properties | $0 | $0 |
| Finished Goods | $21,382,000 | $4,925,000 |
| Work In Process | $14,064,000 | $9,666,000 |
| Raw Materials | $12,348,000 | $7,317,000 |
Fetched: 2026-02-06
Cash Flow Statement (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $50,523,000 | $27,896,000 |
| Operating Activities | ||
| Operating Cash Flow | $50,701,000 | $28,219,000 |
| Cash Flow From Continuing Operating Activities | $50,701,000 | $28,219,000 |
| Operating Gains Losses | $9,863,000 | $5,484,000 |
| Investing Activities | ||
| Capital Expenditure | $-178,000 | $-323,000 |
| Investing Cash Flow | $-86,830,000 | $-5,323,000 |
| Cash Flow From Continuing Investing Activities | $-86,830,000 | $-5,323,000 |
| Net Other Investing Changes | - | $-5,000,000 |
| Financing Activities | ||
| Repurchase Of Capital Stock | $-18,004,000 | $-21,213,000 |
| Financing Cash Flow | $-6,209,000 | $-28,392,000 |
| Cash Flow From Continuing Financing Activities | $-6,209,000 | $-28,392,000 |
| Net Other Financing Charges | $-2,716,000 | $-1,577,000 |
| Net Common Stock Issuance | $-18,004,000 | $-21,213,000 |
| Other | ||
| Repayment Of Debt | $-67,236,000 | $-8,000,000 |
| Issuance Of Debt | $80,000,000 | $0 |
| Interest Paid Supplemental Data | $1,726,000 | $1,197,000 |
| Income Tax Paid Supplemental Data | $28,410,000 | $10,005,000 |
| End Cash Position | $55,321,000 | $97,659,000 |
| Beginning Cash Position | $97,659,000 | $103,155,000 |
| Changes In Cash | $-42,338,000 | $-5,496,000 |
| Proceeds From Stock Option Exercised | $1,747,000 | $2,398,000 |
| Common Stock Payments | $-18,004,000 | $-21,213,000 |
| Net Issuance Payments Of Debt | $12,764,000 | $-8,000,000 |
| Net Short Term Debt Issuance | $15,000,000 | $0 |
| Short Term Debt Payments | $-15,000,000 | $0 |
| Short Term Debt Issuance | $30,000,000 | $0 |
| Net Long Term Debt Issuance | $-2,236,000 | $-8,000,000 |
| Long Term Debt Payments | $-52,236,000 | $-8,000,000 |
| Long Term Debt Issuance | $50,000,000 | $0 |
| Net Investment Purchase And Sale | $-12,500,000 | $0 |
| Purchase Of Investment | $-12,500,000 | $0 |
| Net Business Purchase And Sale | $-74,152,000 | $0 |
| Purchase Of Business | $-74,152,000 | $0 |
| Net PPE Purchase And Sale | $-178,000 | $-323,000 |
| Purchase Of PPE | $-178,000 | $-323,000 |
| Change In Working Capital | $-16,404,000 | $9,537,000 |
| Change In Other Working Capital | $-18,624,000 | $-1,321,000 |
| Change In Payables And Accrued Expense | $46,546,000 | $17,932,000 |
| Change In Accrued Expense | $43,580,000 | $7,770,000 |
| Change In Payable | $2,966,000 | $10,162,000 |
| Change In Account Payable | $2,966,000 | $10,162,000 |
| Change In Prepaid Assets | $-5,155,000 | $-2,770,000 |
| Change In Inventory | $-8,339,000 | $-13,833,000 |
| Change In Receivables | $-30,832,000 | $9,529,000 |
| Changes In Account Receivables | $-30,832,000 | $9,529,000 |
| Other Non Cash Items | $1,449,000 | $2,128,000 |
| Stock Based Compensation | $16,451,000 | $19,555,000 |
| Deferred Tax | $-8,324,000 | $-3,618,000 |
| Deferred Income Tax | $-8,324,000 | $-3,618,000 |
| Depreciation Amortization Depletion | $12,024,000 | $3,760,000 |
| Depreciation And Amortization | $12,024,000 | $3,760,000 |
| Amortization Cash Flow | $11,378,000 | $2,996,000 |
| Amortization Of Intangibles | $11,378,000 | $2,996,000 |
| Depreciation | $646,000 | $764,000 |
| Earnings Losses From Equity Investments | $4,457,000 | $6,170,000 |
| Gain Loss On Investment Securities | $962,000 | $-686,000 |
| Net Income From Continuing Operations | $35,642,000 | $-8,627,000 |
Fetched: 2026-02-06